Related Experiment Video
Updated: May 5, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
5.7K
Multi-Omics Analyses Identify ANLN as a Prognostic Biomarker for Recurrence and Metastasis in Non-Small Cell Lung
Haiwei Quan1,2, Zhiguang Xu2, Lizhen Huo1,2
1Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.
Genes
|May 4, 2026
Summary
The gene ANLN drives lung cancer recurrence and metastasis by promoting cell proliferation and invasion. Targeting ANLN pathways offers potential new therapeutic strategies for lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Lung cancer recurrence and metastasis are primary causes of cancer mortality.
- Molecular drivers of lung cancer progression are not fully understood.
- Integrative transcriptomic analysis is crucial for identifying key regulators.
Purpose of the Study:
- Identify key regulators of lung cancer progression.
- Analyze molecular determinants of recurrence and metastasis.
- Explore therapeutic targets for lung cancer.
Main Methods:
- Integrated bulk and single-cell RNA sequencing data from multiple cohorts.
- Prioritized progression-related genes by analyzing tumor microenvironment.
- Validated ANLN function using CRISPR-Cas9 and performed drug prediction.
Main Results:
- ANLN identified as a core progression gene linked to poor prognosis and worse survival.
- ANLN upregulation in recurrent/metastatic tumors associated with invasive phenotype and proliferation.
- ANLN deletion reduced proliferation and induced apoptosis; Trifluridine and Monobenzone identified as potential drugs.
Conclusions:
- ANLN regulates lung cancer recurrence and metastasis, marking an invasion-prone state.
- ANLN-associated pathways are potential therapeutic targets for lung cancer.
- Further research into ANLN inhibitors may yield novel treatments.
